State Board of Administration of Florida Retirement System boosted its position in shares of Catalent, Inc. (NYSE:CTLT) by 15.7% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 92,033 shares of the company’s stock after buying an additional 12,463 shares during the quarter. State Board of Administration of Florida Retirement System owned approximately 0.07% of Catalent worth $3,674,000 as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of the business. Advisor Group Inc. lifted its holdings in Catalent by 1.3% during the 2nd quarter. Advisor Group Inc. now owns 5,185 shares of the company’s stock worth $180,000 after buying an additional 65 shares in the last quarter. Stifel Financial Corp lifted its holdings in Catalent by 0.9% during the 2nd quarter. Stifel Financial Corp now owns 10,694 shares of the company’s stock worth $377,000 after buying an additional 96 shares in the last quarter. Aperio Group LLC lifted its holdings in Catalent by 0.8% during the 2nd quarter. Aperio Group LLC now owns 23,088 shares of the company’s stock worth $810,000 after buying an additional 190 shares in the last quarter. Capstone Asset Management Co. lifted its holdings in Catalent by 2.3% during the 2nd quarter. Capstone Asset Management Co. now owns 10,130 shares of the company’s stock worth $356,000 after buying an additional 230 shares in the last quarter. Finally, People s United Financial Inc. lifted its holdings in Catalent by 1.9% during the 2nd quarter. People s United Financial Inc. now owns 18,952 shares of the company’s stock worth $665,000 after buying an additional 356 shares in the last quarter. 95.65% of the stock is currently owned by hedge funds and other institutional investors.
In related news, SVP Christine Dolan sold 1,594 shares of the company’s stock in a transaction on Tuesday, August 29th. The shares were sold at an average price of $38.75, for a total value of $61,767.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 1.70% of the stock is owned by corporate insiders.
CTLT has been the subject of several recent research reports. Needham & Company LLC reiterated a “hold” rating on shares of Catalent in a research report on Monday, October 23rd. Zacks Investment Research cut shares of Catalent from a “buy” rating to a “hold” rating in a research report on Friday, November 3rd. BidaskClub upgraded shares of Catalent from a “hold” rating to a “buy” rating in a research report on Thursday, October 5th. ValuEngine upgraded shares of Catalent from a “hold” rating to a “buy” rating in a research report on Thursday, September 7th. Finally, Piper Jaffray Companies upped their target price on shares of Catalent from $45.00 to $50.00 and gave the company an “overweight” rating in a research report on Tuesday, November 7th. Five analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $42.11.
Shares of Catalent, Inc. (NYSE:CTLT) opened at $37.27 on Wednesday. The company has a debt-to-equity ratio of 2.01, a current ratio of 2.91 and a quick ratio of 2.49. Catalent, Inc. has a 1 year low of $22.94 and a 1 year high of $43.39. The company has a market cap of $5,048.66, a price-to-earnings ratio of 26.57, a P/E/G ratio of 2.44 and a beta of 1.49.
Catalent (NYSE:CTLT) last released its quarterly earnings data on Monday, November 6th. The company reported $0.21 EPS for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.01. Catalent had a net margin of 5.01% and a return on equity of 23.97%. The business had revenue of $543.90 million during the quarter, compared to analysts’ expectations of $490.75 million. During the same quarter in the prior year, the company earned $0.16 EPS. The firm’s quarterly revenue was up 23.0% on a year-over-year basis. research analysts expect that Catalent, Inc. will post 1.46 earnings per share for the current year.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.